HenryCPitotMD

PubMed

• Resection of a Solitary Right Ventricular Metastasis in Oligorecurrent Hepatocellular Carcinoma.
  Ergi, D., Klarich, K., Dearani, J., Crestanello, J., Maleszewski, J., Morris, J., Young, P., Callaghan, C., Pitot, H., Arghami, A.> ;Journal of Clinical Medicine. 2023 Dec 6
• Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
  Sri Harsha Tella, Nathan Foster, Shi Qian, Tran Nguyen, Mitesh J Borad, Robert R McWilliams, Steven R Alberts, Wen Wee Ma, Sakti Chakrabarti, Briant Fruth, Jaclynn Wes...> ;The Oncologist. 2023 Oct 3
• 20 citations
  Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
  Mojun Zhu, Chunhua Chen, Nathan R Foster, Christopher Hartley, Taofic Mounajjed, Marcela A Salomao, Briant F Fruth, Staci E Beamer, Yohan Kim, Susan M Harrington, Henr...> ;Clinical Cancer Research. 2022 Jul 15
• 3 citations
  Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.
  Nadine J McCleary, William S Harmsen, Ellana Haakenstad, James M Cleary, Jeffrey A Meyerhardt, John Zalcberg, Richard Adams, Axel Grothey, Alberto F Sobrero, Eric Van ...> ;JNCI Cancer Spectrum. 2022 Mar 2
• 10 citations
  Estrogen Receptor-α Suppresses Liver Carcinogenesis and Establishes Sex-Specific Gene Expression
  Mara H O'Brien, Henry C. Pitot, Sang-Hyuk Chung, Paul F. Lambert, Norman R. Drinkwater, Andrea Bilger> ;Cancers. 2021 May 13
• 13 citations
  Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.
  Lionel A. Kankeu Fonkoua, Sakti Chakrabarti, Mohamad Bassam Sonbol, Pashtoon Murtaza Kasi, Jason S. Starr, Alex J. Liu, Wendy K. Nevala, Rachel L. Maus, Melanie C. Boi...> ;International Journal of Cancer. 2021 Jul 15
• 4 citations
  Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.
  Caleb J. Smith, Tanios Bekaii-Saab, Kathryn D. Cook, Rachel A. Eiring, Thorvardur R. Halfdanarson, Mina Samir Erian Hanna, Zhaohui Jin, Jacob A. Jochum, Wen Wee Ma, Je...> ;Pancreatology. 2021 Mar 1
• 2 citations
  Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer.
  Daniel S. Childs, Harry H. Yoon, Rachel A. Eiring, Zhaohui Jin, Jacob A. Jochum, Henry C. Pitot, Aminah Jatoi> ;Supportive Care in Cancer. 2021 Feb 1
• 17 citations
  Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
  Angela L. McCleary-Wheeler, Ryan M. Carr, Shanique R. Palmer, Thomas C. Smyrk, Jacob B. Allred, Luciana L. Almada, Ezequiel J. Tolosa, Maria J. Lamberti, David L. Mark...> ;Pancreatology. 2020 Jan 1
• 16 citations
  Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.
  Karthik V. Giridhar, Carlos P. Sosa, David W. Hillman, Cristobal T. Sanhueza, Candace Lee Dalpiaz, Brian A. Costello, Fernando Quevedo, Henry C. Pitot, Roxana S. Dronc...> ;International Journal of Molecular Sciences. 2017 Nov 3
• 60 citations
  A Prospective Genome-Wide Study of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation and Increased Cell Cycle Proliferation with Primary Resista...
  Liguo Wang, Scott M. Dehm, David W. Hillman, Hugues Sicotte, Winston Tan, Michael Gormley, Vipul Bhargava, Rafael E. Jimenez, Fang Xie, Ping Yin, Sisi Qin, Fernando Qu...> ;Annals of Oncology. 2018 Feb 1
• 99 citations
  Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
  Manish Kohli, Yeung Ho, David W. Hillman, Jamie L. Van Etten, Christine Henzler, Rendong Yang, Jamie M. Sperger, Yingming Li, Elizabeth Tseng, Ting Hon, Tyson A. Clark...> ;Clinical Cancer Research. 2017 Aug 15
• LBA-003Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
  Bendell, J.,Hubbard, J.,O'Neil, B. H.,Jonker, D.,Starodub, A.,Peyton, J.,Pitot, H.,Halfdanarson, T.,Nadeau, B.,Zubkus, J.,Adesunloye, B.,Edenfield, J.,Li, Y. Z.,Li, W....> ;Ann. Oncol.. 2018 Jul 28
• 51 citations
  Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
  Nilofer S. Azad, Anthony B. El-Khoueiry, Jun Yin, Ann L. Oberg, Patrick J. Flynn, Douglas Adkins, Anup Sharma, Daniel J. Weisenberger, Thomas M. Brown, Prakriti Medvar...> ;Oncotarget. 2017 Feb 6
• 15 citations
  Loss of Dependence on Continued Expression of the Human Papillomavirus 16 E7 Oncogene in Cervical Cancers and Precancerous Lesions Arising in Fanconi Anemia Pathway-De...
  Soyeong Park, Jung-Wook Park, Henry C. Pitot, Paul F. Lambert> ;Mbio. 2016 Jul 6
• 60 citations
  Role of Ultraviolet Radiation in Papillomavirus-Induced Disease
  Aayushi Uberoi, Satoshi Yoshida, Ian H. Frazer, Henry C. Pitot, Paul F. Lambert> ;Plos Pathogens. 2016 May 31
• 1 citations
  Ureteral obstruction in cancer patients: a qualitative study.
  Amanika Kumar, Lance A. Mynderse, Krishna Patel, Megan Grudem, Jamie N. Bakkum-Gamez, Sherri Longenbach, Matthew S. Block, Henry C. Pitot, Vesna D. Garovic, S. John We...> ;Psycho-Oncology. 2016 May 1
• 202 citations
  Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
  Carmen J. Allegra, Greg Yothers, Michael O’Connell, Robert W. Beart, Timothy F. Wozniak, Henry C. Pitot, Anthony F. Shields, Jerome C. Landry, David P. Ryan, Amit Aror...> ;Journal of the National Cancer Institute. 2015 Nov 1
• 49 citations
  Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
  Herbert Hurwitz, David Smith, Henry C. Pitot, Jeffrey Mark Brill, Rashmi Chugh, Elisabeth Rouits, Joseph Rubin, John H. Strickler, Gregoire Vuagniaux, J. Mel Sorensen,...> ;Cancer Chemotherapy and Pharmacology. 2015 Feb 27
• 12 citations
  Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consor...
  Jaime R. Merchan, Rui Qin, Henry C. Pitot, Joel Picus, Glenn Liu, Tom R. Fitch, William J. Maples, Patrick J. Flynn, Briant Fruth, Charles Erlichman> ;Cancer Chemotherapy and Pharmacology. 2015 Jan 3
• 33 citations
  Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent on the aryl hydrocarbon receptor and TNF/IL-1 receptors.
  Gregory D. Kennedy, Manabu Nukaya, Susan M. Moran, E.W.N. Glover, Samuel E. Weinberg, Silvia Balbo, Stephen S. Hecht, Henry C. Pitot, Norman R. Drinkwater, Christopher...> ;Toxicological Sciences. 2014 Jul 1
• 288 citations
  Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project...
  Michael J. O'Connell, Linda H. Colangelo, Robert W. Beart, N. J. Petrelli, Carmen J. Allegra, Saima Sharif, Henry C. Pitot, Anthony F. Shields, Jerome C. Landry, David...> ;Journal of Clinical Oncology. 2014 Jun 20
• 53 citations
  A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
  Roberto Pili, Rui Qin, Patrick J. Flynn, Joel Picus, Michael Millward, Wing M. Ho, Henry C. Pitot, Winston Tan, Kiersten Marie Miles, Charles Erlichman, Ulka N. Vaisha...> ;Clinical Genitourinary Cancer. 2013 Dec 1
• 5783 citations
  Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
  Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John S. Kauh, Kunle Odunsi, Henry...> ;The New England Journal of Medicine. 2012 Jun 28
• 63 citations
  Phase 2 Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer
  Philip A. Philip, Michelle R. Mahoney, Kyle D. Holen, Donald W. Northfelt, Henry C. Pitot, Joel Picus, Patrick J. Flynn, Charles Erlichman> ;Cancer. 2012 May 1
• Join now to see all

Journal Articles

• Phase 2 study of bevicizumab plus erlotinib in patients with advanced hepatocellular cancer  
  Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C, Cancer, 1/1/2011
• Use of KW-2189, a DNA Minor Groove-Binding Agent, in Patients with Hepatocellular Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Clinical Trial  
  Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J, Int J Gastrointest Cancer, 1/3/2008
• The Phan/Yao article reviewed--Small steps forward in the land of small tumors  
  Hobday TJ, Pitot HC, Oncology, 1/1/2008
• Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors  
  Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C, J Clin Oncol, 1/1/2002
• Future directions in adjuvant therapy for stage III colon carcinoma  
  Pitot HC, Goldberg RM, Oncology, 1/1/2001
• An NCCTG Phase II Trial of 9-Amino Camptothecin in Previously Untreated Patients With Measurable Metastatic Colorectal Cancer  
  Pitot H, Knost J, Mahoney M, Kugler J, Krook J, Hatfield A, Goldberg R, Sargent D, Cancer, 1/1/2000
• The Damjanov/Meropol article reviewed  
  Pitot HC, Goldberg RM, Oncology, 1/1/2000
• Treatment of advanced colorectal carcinoma  
  Pitot HC, Mayo Clinical Update, 1/1/1997
• Join now to see all

Books/Book Chapters

• Mayo Internal Medicine Board Review 2002-03 
  Chapter: Chapter 19: Oncology 
  Okuno SH, Pitot HCEditors: Thomas M, Habermann MD.Lippincott Williams & Wilkins2002
• Mayo Internal Medicine Board Review 2000-01 
  Chapter: Chapter 18: Oncology 
  Okuno SH, Pitot HCEditors: Udaya BS, Prakash MD.Lippincott Williams & Wilkins2000
• Cancer Chemotherapy and Biological Response Modifiers/13 
  Chapter: Breast Cancer 
  Pitot H, Loprinzi CLEditors: Pinedo HM, et al..Elsevier Science Publishers, Amsterdam1992

Lectures

• Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P) 
  San Francisco, CA - 1/1/2016
• The association of JAK2 polymorphisms with prognosis in castration-resistant prostate cancer (CRPC) 
  San Francisco, CA - 1/1/2016
• Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P) 
  Chicago, IL - 1/1/2016
• Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advance... 
  Chicago, IL - 1/1/2016
• Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors 
  Chicago, IL - 1/1/2015
• First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results 
  Chicago, IL - 1/1/2014
• Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC) 
  Orlando, FL - 1/1/2013
• A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study 
  Chicago, IL - 1/1/2013
• Association of germ-line genetic variation with failure of androgen ablation (AA) in hormone-sensitive advanced prostate cancer 
  Chicago, IL - 1/1/2013
• PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors 
  Chicago, IL - 1/1/2012
• Different Treatment Options for Metastatic Urothelial Carcinoma 
  Santiago, Chile - 1/12/2011
• Neoadjuvant and Adjuvant Treatment of Bladder Cancer 
  Santiago, Chile - 1/12/2011
• The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 
  Chicago, IL - 1/1/2011
• MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer 
  Orlando, FL - 1/1/2011
• Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma 
  Orlando, FL - 1/1/2011
• Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449 
  Orlando, FL - 1/1/2011
• Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841 
  Chicago, IL - 1/1/2011
• Anti-B7-H1 Clinical Trial 
  Rochester, MN - 1/26/2010
• Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors 
  Orlando, FL - 1/1/2009
• Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients 
  Orlando, FL - 1/1/2009
• Liver Cancer 
  Rochester, MN - 1/1/2008
• Management of Prostate Cancer 
  Kauai, HI - 1/1/2006
• Symptom Management in Cancer Patients 
  Kauai, HI - 1/1/2006
• N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Paitents with Advanced Colorectal Carcinoma Previously Treated with 5-Fluorour... 
  Orlando, FL - 1/1/2005
• The IRB and Its Role in Protecting Human Subjects 
  Rochester, MN, 2003 - 1/1/2004
• Join now to see all